전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved169 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleRochePhase 3

HLX87 + Pertuzumab (HLX87 + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#HER2+BreastCancer+1
Trials 2Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, MK-2206 with or without Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 2Status Recruiting
AntibodyLimited DatastaleMargaret Gatti-MaysPhase 2

Naxitamab (Naxitamab)

Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AnatomicStageIVBreastCancerAJCCv+2
Trials 2Status Recruiting
CGTLimited DatastaleGuangdong ProCapZoom Bioscience…Phase 1

SZ011 CAR-NK (SZ011 CAR-NK)

Ovarian Epithelial Carcinoma · Advanced Triple Negative Breast Cancer

#AdvancedTripleNegativeBreastCanc#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Recruiting
AntibodyLimited DatastaleNeovii BiotechPhase 2

ertumaxomab (ertumaxomab)

Metastatic Breast Cancer; Advanced Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#monoclonal-antibody#AdvancedBreastCancer+1
Trials 2Status Discontinued
ADCLimited DatastaleJiangsu HengruiPhase 2

A2: SHR-A1811 with Camrelizumab with famitinib (A2: SHR-A1811 with Camrelizumab with famitinib)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#antibody-drug-conjugate#Jiangsu
Trials 1Status Recruiting
CGTLimited DatastaleGuangzhou Anjie Biomedical Tech…Phase 2

AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)

Advanced Breast Cancer; Breast Neoplasm Malignant Female · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

trastuzumab (Herceptin, AMG 386 with or without Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Recruiting
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

ARX788 + Cemiplimab (ARX788 + Cemiplimab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER, Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor, Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Active
AntibodyLimited DatastaleRochePreclinical

trastuzumab (Herceptin, Ado-trastuzumab emtamsine)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#monoclonal-antibody#Roche
Trials 1Status Recruiting
CGTLimited DatastaleCytoMed Therapeutics Pte LtdPhase 1

Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell (Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell)

Colorectal Cancer; Triple Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleZhi YangPhase 2

Anti-HER2 CAR-T (Anti-HER2 CAR-T)

Breast Cancer; Ovarian Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + RP1)

Triple Negative Breast Neoplasms · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Discontinued
ADCLimited DatastaleFudan UniversityPhase 2

B2: TROP2 ADC with Camrelizumab (B2: TROP2 ADC with Camrelizumab)

Triple-negative Breast Cancer · TROP2

#TROP2#ADC#Phase2#antibody-drug-conjugate#Triple-negativeBreastCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleYuan YuanPhase 2

Balstilmab (Balstilmab)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase2#monoclonal-antibody#MetastaticTriple-NegativeBreastC+1
Trials 1Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Intrapleural (CEA-targeted CAR-T, CEA-targeted CAR-T (Intrapleural))

NSCLC (Advanced Non-small Cell Lung Cancer); Breast Cancer · CEA

#CEA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Intravenous (CEA-targeted CAR-T, CEA-targeted CAR-T (Intravenous))

NSCLC (Advanced Non-small Cell Lung Cancer); Breast Cancer · CEA

#CEA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleBiogenPhase 1

trastuzumab (Herceptin, CNF2024 + trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#monoclonal-antibody#Biogen
Trials 1Status Active
AntibodyLimited DatastaleBristol-Myers SquibbPhase 2

Cabiralizumab (Cabiralizumab)

Advanced Pancreatic Cancer · Triple Negative Breast Cancer

#TripleNegativeBreastCancer#Antibody#Phase2#monoclonal-antibody#AdvancedPancreaticCancer+1
Trials 1Status Active

4 / 9 pages

← PreviousNext →